Article
When Cold Is Hot: Immune Checkpoint Inhibition Therapy for Rhabdoid Tumors.
Cancer cell - 9 Dec 2019
Yarmarkovich Mark, Maris John M
Abstract excerpt
Carcinogen-induced cancers typically have high mutation burdens and an inflamed microenvironment and thus are poised to respond to immune checkpoint inhibitors (ICIs). However, cancers with loss-of-function mutations in the SWI/SNF complex have few additional mutations yet also have an inflamed immunophenotype and should respond to ICI therapy.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
